Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


User Fee Goals For Recently Announced NDA/BLA Submissions

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

User Fee Goals For Recently Announced NDA/BLA Submissions

You may also be interested in...

Oral Zemplar NDA Submission, Hectorol Launch Heat Up Pre-Dialysis Market

Expanding the use of vitamin D analogs to earlier-stage chronic kidney disease patients will be a frequent topic of promotional activity in coming months, as Abbott prepares the market for its recently filed oral formulation of Zemplar and Bone Care International begins launch of a new version of Hectorol.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

September 2010 Approvals






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts